Regeneron Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
Regeneron Pharmaceuticals, Inc. income statement - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue14.3414.2013.1212.1716.078.506.565.15
Cost of Revenue2.101.971.825.155.303.770.400.42
Gross Profit12.2412.2311.307.0210.774.736.154.73
Operating Expenses
Research & Development5.855.234.633.852.862.742.451.47
Selling, General & Administrative2.702.952.632.121.821.351.341.13
Operating Expenses8.548.247.252.031.781.073.582.19
Operating Income3.703.994.054.998.993.662.212.53
Other Income/Expense
Interest Income0.720.710.500.160.050.080.000.00
Interest Expense0.040.060.07-0.06-0.06-0.060.000.03
Other Income/Expense0.860.79-0.270.010.000.02-0.250.05
Income
Income Before Tax5.234.784.204.869.333.812.432.55
Income Tax Expense0.730.370.250.521.250.300.310.11
Net Income4.504.413.954.348.083.512.122.44
Net Income - Continuous Operations4.504.413.954.348.080.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.000.00
EBITDA5.825.324.695.349.283.902.672.73
EBIT5.274.844.274.998.993.662.462.58
Depreciation & Amortization0.540.480.420.340.290.240.000.00
Earnings Per Share
Basic EPS43.0041.0037.0041.0076.0033.0019.0023.00
Diluted EPS41.0038.0035.0038.0072.0031.0018.0021.00
Basic Shares Outstanding0.100.110.110.110.110.110.110.11
Diluted Shares Outstanding0.110.120.110.110.110.120.110.11